Key result
Possession of an APOE epsilon4 allele predicted earlier and faster cognitive decline in Alzheimer disease in a dose-response manner, whereas the APOE epsilon2 allele was protective.
Why the study?
Does APOE genotype predict the rate of cognitive decline in patients with Alzheimer disease?
Population
218 patients with Alzheimer disease
Comparison
APOE genotype (epsilon4 and epsilon2 alleles) vs Different APOE alleles
Design
Cohort
Authors
Loading...
APOE genotyping may refine prognostic counseling in Alzheimer disease; leaves open whether it guides therapy or trial enrichment.
Cohort (n=218)
Does APOE genotype predict the rate of cognitive decline in patients with Alzheimer disease?
APOE genotype strongly predicts the rate of cognitive decline in Alzheimer disease, with epsilon4 accelerating and epsilon2 slowing the decline, best modeled nonlinearly.
Martins et al. (2005) conducted a cohort in Alzheimer disease (n=218). APOE genotype was evaluated on Rate of cognitive decline. Possession of an APOE epsilon4 allele predicted earlier and faster cognitive decline in Alzheimer disease in a dose-response manner, whereas the APOE epsilon2 allele was protective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: